Pleiotrophin Regulates Normal and Leukemic Hematopoietic Stem Cell Fate  by Himburg, H.A. et al.
S236 Oral Presentations89
PLEIOTROPHIN REGULATES NORMAL AND LEUKEMIC HEMATOPOIETIC
STEM CELL FATE
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We recently demonstrated the cytokine pleiotrophin (PTN) is
a growth factor for hematopoietic stem cells (HSCs) in vitro and sys-
temic administration of PTN is sufficient to accelerate HSC regen-
eration following injury in vivo (Himburg, Nat Med 2010). To
determine whether PTN signaling is necessary for maintenance of
the HSC pool in vivo, we characterized the HSC content of
mice bearing a constitutive deletion of PTN. PTN-/- mice have sig-
nificantly decreased phenotypic HSC content and competitive repo-
pulating transplantation assays confirmed a 7-fold reduction in
long-term HSCs. Transplantation of wild type BM cells into
PTN+/+ versus PTN-/- mice and analysis of these chimeric mice
(WT;PTN-/-) demonstrated that decrease in HSC content was de-
pendent upon the BM microenvironment. The WT:PTN-/- mice
had 5-fold less competitive repopulating ability compared to
WT:PTN+/+ controls, thus confirming the role of the microenvi-
ronment in PTN signaling. Since PTN was not previously known
to be produced within the HSC niche, we next sought to identify
which cells within the BMproduce PTNusing a PTN-GFP reporter
mouse.We determined that PTN is discretely produced throughout
the bone marrow by VEGFR3+ endothelial cells, CXCL12+ cells,
but is absent on osterix+ pre-osteoblasts. These data suggest that
PTN is an important physiologic regulator of HSC fate in the
HSC niche. Since PTN regulates normal hematopoiesis, we hypoth-
esized that it might also be important in the regulation of leukemic
stem cell fate. We induced a blast crisis CML phenotype in
PTN-/- and WT HSCs using a retrovirus to introduce the
Nup98/HoxA9 and BCR/ABL genetic mutations (Neering, Blood
2007; Ito T, Nature 2010). The BC-CML cells generated from
PTN-/- cells had significantly reduced leukemic colony formation
in a methylcellulose assay compared to transformedWT cells. Addi-
tionally, PTN-/- mice transplanted with PTN-/- leukemic cells
demonstrated prolonged median survival compared to WT mice
transplanted withWT BC-CML cells. Secondary mice transplanted
with the BC-CML cells isolated from the primary spleens demon-
strated significantly increased survival in the PTN-/- group com-
pared to the control group. The PTN-/- mice had significantly
reduced phenotypic leukemia stem cell (LSC) content (CD150-
sca1+lin-) in the bone marrow as well as significantly smaller spleens
than the WT transplanted mice. These data suggest that PTN is an
important regulator of both normal and leukemic stem cell fate in
vivo.90
USING PROTEOMICS ANALYSIS TO IDENTIFY NOVEL PROTEINS IN MAR-
ROW NICHE MICROENVIRONMENT THAT CONTRIBUTE TO THE EN-
HANCED DONOR CELL ENGRAFTMENT WITH PLERIXAFOR TREATMENT
An, N., Bland, A., Lazarchick, J., Li, Z., Kraft, A., Arthur, J., Kang, Y.
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Enhancing donor cell recovery is a very important goal in hemato-
poietic stem cell transplantation (HCT). Hematopoiesis is regulated
by marrow niche microenvironment. We recently found that post
transplant administration of plerixafor (a specific and reversible
CXCR4 antagonist) enhanced donor cell engraftment and promoted
recovery of all donor cell lineages in a congeneic mouse transplant
model (Kang et al, 2010, PLoS One 5, e11316). We hypothesized
that plerixafor enhances donor cell reconstitution in part by modu-
lating the levels and constitution of soluble factors in niche microen-
vironment. To test this hypothesis, we transplanted lethally
irradiated C57Bl/6 mice with sorted c-Kit+ Lin- Sca-1+ HSCs and
then injected s.c. PBS or plerixafor (5 mg/kg) every other day begin-
ning at day +2 post transplant. At day +7 post transplant, the mice
were sacrificed. Tibias and femurs were flushed with PBS, centri-
fuged, and marrow supernatants were collected. We found that the
marrow supernatants of PBS treated- transplant mice inhibited
bone marrow cell (BMC) colony forming units (CFUs). In contrast,the marrow supernatants of plerixafor treated- mice significantly in-
creased BMC CFUs, and plerixafor per se had no effects on CFUs.
We next used a mass spectrometry-based, quantitative, label-free
proteomics approach to compare the protein expression in marrow
supernatant of PBS treated- transplant mice with that from plerixa-
for treated- mice. We identified a total of 289 proteins, 3 of them
only present in the marrow supernatants of PBS treated- transplant
mice. Twenty-three proteins were increased (more than 2 fold)
and 7 decreased in plerixafor treated- transplant mice. We then per-
formed additional studies to validate our proteomics results. We fo-
cused on thioredoxin, one of the 23 proteins that increased in the
marrow supernatant of plerixafor treated- transplant mice. Thiore-
doxin is a small oxidoreductase protein important in preserving tis-
sue redox homeostasis and cellular integrity. We found that
thioredoxin mRNA expression in BMCs was up-regulated with pler-
ixafor treatment. Furthermore, we found that thioredoxin increased
BMC CFUs, enhanced recovery of platelet count in sublethally
irradiated mice, and protected against radiation-related death. Our
results demonstrated that factors in the marrow niche microenviron-
ment play a critical role in hematopoiesis. Our study provides clue
on potential novel targets that can be used to further enhance
hematopoiesis.SUPPORTIVE CARE91
GENERATION OF RED BLOOD CELLS FROM HUMAN EMBRYONIC STEM
CELLS (ES) WITH INCREASED EFFICACY
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It is estimated that for every unit of donated blood, two units are
required in North America. The current rate of blood donation is
stagnant, while the need increases by 6-8% annually. In order to
overcome this difficulty, we have developed an improved method
to generate red blood cells from human embryonic stem cells (ES)
with increased efficacy. In addition to xeno-free conditions and stan-
dard cytokine cocktail used for hematopoietic differentiation of hu-
manES cells (Carrier et al, JTM2009), we have introduced amethod
of growth and differentiation of human ES cells with hypoxia-in-
duced mesenchymal stem cells, obtained from allogeneic adult
bone marrow donors. This technique increased the efficacy of red
blood cell generation 5-25 fold.
In collaboration with DnaMicroarray, Inc, we have developed
a microspheres-based culture system with highly porous surface al-
lowing culturing of a very large number of embryonic stem cells
per one culture conditions. This culture system avoids shear forces
and damage to the cells, and facilitates removal and recycling of
the microspheres. The re-feeding of cells is automatic and does
not require human effort. Depending on the size of the bioreactor
large number of red cells can be obtained with this system (5L,
10L, 50L, 100L). The in vitro obtained human ES-derived red blood
cells are enucleated and will not produce tumors in vitro (efficacy of
enucleation is 65-95%). The laser-based system will be utilized to
eliminate nucleated cells from the culture.
The problemwith hES-derived red blood cells is that they are pro-
duced in small numbers and the process is very costly. We are devel-
oping a 3-phase bioreactor with computerized programming, which
will increase every step of the differentiation process and allow recy-
cling of feeder cells and cytokines in a sheer-free process. This sys-
tem will generate 1 unit of blood (2x1012) (RBC) per hour. We
will utilize iron-loaded microspheres coated with hypoxia-processed
mesenchymal stem cells as a main culture unit. Thus, the cost of 1
unit of blood will be markedly decreased. Special laser-based cham-
ber (Cyntellect) will be used to eliminate residual progenitors with
nuclei. This bioreactor system with recycling of expensive cytokines
will allow production of the off-shelf, ORh- red blood cells in a cost
effective manner and in a large amounts, thus allowing its clinical
use.
